Biocryst Pharmaceuticals
Clinical trials sponsored by Biocryst Pharmaceuticals, explained in plain language.
-
Hope for youngest HAE patients: daily pill aims to stop dangerous swelling
Disease control OngoingThis study is testing a daily oral medication called berotralstat to prevent painful and dangerous swelling attacks in children aged 2 to 12 with hereditary angioedema (HAE). Researchers are finding the right dose based on a child's weight and checking how safe the drug is for yo…
Phase: PHASE3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Patients get extended access to promising HAE drug in 10-Year safety study
Disease control ENROLLING_BY_INVITATIONThis study provides continued access to the oral medication berotralstat for people with hereditary angioedema (HAE) who were in previous trials. It aims to monitor the long-term safety and tolerability of the drug for up to 10 years in adults and adolescents, and up to 5 years i…
Phase: PHASE3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC